[Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
Kaizu
Kazo
K
Kidney Center, University Hospital of Occupational and Environmental Health, Japan.
Uriu
Kohei
K
Ikeda
Masanori
M
D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D001550:Benzamidines; D001777:Blood Coagulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005112:Extracorporeal Circulation; D005342:Fibrinolysis / Q000187:drug effects*; D016670:Gabexate / Q000008:administration & dosage* / Q000494:pharmacology; D006146:Guanidines / Q000008:administration & dosage* / Q000494:pharmacology; D006493:Heparin / Q000008:administration & dosage* / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects*; D006435:Renal Dialysis
D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; D006495:Heparin, Low-Molecular-Weight; D016670:Gabexate; D006493:Heparin; C032855:nafamostat